US rival Eli Lilly last month forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, leading the stock to fall 8%. The shares have since recovered. "We see an ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.

While you may not be familiar with the term "GLP-1," I'd wager you'll recognize some of the most popular ones on the market today, including Ozempic, Wegovy, Mounjaro, and Zepbound. Each of these ...

Zepbound is a GLP-1 agonist containing tirzepatide ... and 3.2% (with diabetes). Starting dose: 2.5 mg weekly, increasing to 5 mg after 4 weeks. Doses may continue to increase to a maximum ...

On Tuesday, the agency gave the green light for Ozempic to help protect kidney function in people with diabetes and Zepbound as the first-ever drug treatment for sleep apnea in people with obesity.

GLP-1 drugs are a class of prescription medications such as Ozempic, Wegovy, Mounjaro, and Zepbound, that helps regulate blood sugar by boosting insulin production. Josh Gad visits World of Frozen ...

also called a Zepbound pen. The vial doses available are 2.5 mg and 5 mg, which is limited compared to the six Zepbound pen doses. Single-dose vials may be less convenient than an auto-injector pen.

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Some people who may not be able to receive Ozempic include: Zepbound works by activating the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors to mimic hormones that occur in ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...